• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Bracco sells Esaote subsidiary to investment group

Article

Esaote, known worldwide for its MR and ultrasound equipment, has split from its Italian parent, the Bracco Group. The company was sold Jan. 20 for an undisclosed amount to a group of investors led by Esaote chairman and CEO Carlo Castellano.

Esaote, known worldwide for its MR and ultrasound equipment, has split from its Italian parent, the Bracco Group. The company was sold Jan. 20 for an undisclosed amount to a group of investors led by Esaote chairman and CEO Carlo Castellano.

Eighty shareholders in the newly independent Esaote are company staff, described by Castellano as "white collars, managers, and top executives." Castellano gives the company high marks in teamwork and commitment to innovation.

"The key success factors of the Esaote group are the quality of the medical equipment and the know-how in the software applied to diagnostics," he said.

Esaote provides specialty MR scanners dedicated to extremity imaging, as well as diagnostic ultrasound equipment and electrocardiography systems.

The divestment of Esaote reflects efforts by Bracco to focus on core capabilities and selected emerging technologies. The company is concentrating particularly on devices oriented toward the administration of diagnostic contrast agents and high-tech adjuncts to therapy.

Editor's note: DI SCAN will profile Esaote, strategic developments at Bracco, and the deal that split these two companies apart in its next issue, Feb. 6.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.